Consultation on natamycin and its associated end-use products, Proposed Re-evaluation Decision PRVD2024-02

Health Canada is consulting Canadians on the proposal to continue registration of products containing natamycin for sale and use in Canada, with proposed label updates.

Natamycin is registered to suppress dry bubble disease in mushroom production facilities. It is also registered for use as a preservative for samples of milk used in analytical testing laboratories.

Natamycin, also known as pimaricin, is a naturally-occurring antimycotic substance that prevents the germination of fungal spores. It is an important tool for mushroom growers to control integrated dry bubble disease management. It is also important to the dairy industry to preserve milk samples in analytical testing laboratories. Natamycin is also a food preservative that is approved and used in more than 150 countries around the world. Based on the current use pattern, natamycin has value in providing a pest management solution, and the potential risks to human health (dietary, occupational, and bystander) and the environment (aquatic and terrestrial organisms) are considered to be acceptable when products containing natamycin are used according to proposed label updates.

For a full list of products containing natamycin, please consult Appendix I in the Proposed Re-evaluation Decision or visit the Pesticide Label Search database.

For more information on the proposed decision open the "Proposed Re-evaluation Decision".

How to get involved

This consultation is open for comment from 6 March 2024 to 4 June 2024 (90 calendar days).

To comment on PRVD2024-02:

• Step 1: Request the full consultation document to read the Science Evaluation that is the basis of this proposed regulatory decision.
• Step 2: Submit comments to the PMRA Publications Section.

All comments received will be considered. A final re-evaluation decision will consider additional scientific information provided during the public comment period.

Please refer to the document title Proposed Re-evaluation Decision PRVD2024-02, Natamycin and its Associated End-use Products.

Reporting to Canadians

Health Canada will make the results of this consultation available on this website. Once the decision is finalized, the PMRA will post a Re-evaluation Decision on the Pesticides and Pest Management Reports and Publications portion of Canada.ca.

If you have any questions, contact the Pest Management Information Service.

Interested in our other consultations? Sign up and stay informed about topics that matter to you.